![](/imgs/covers/cr_cover.jpg)
|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 1, No. 1, 2005, pp. 46-50
|
Bioline Code: cr05011
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 1, No. 1, 2005, pp. 46-50
en |
Neo-adjuvant chemotherapy with cisplatin and short infusional 5-FU in advanced head and neck malignancies
Aich Ranen Kanti, Deb Asit Ranjan, Ray Amitabh
Abstract
Background
: Combination of radical surgery and radiotherapy is the standard management of head and neck malignancies. But due to considerable morbidity of surgery and associated cosmetic and functional deficiencies, often aggravated by adjuvant radiotherapy, many patients prefer only radiotherapy with its′ decreased chance of survival. Proper surgical facilities are also not accessible to most of our patients. Neo-adjuvant chemotherapy and loco-regional management by surgery and / or radiotherapy have emerged as a viable alternative.
Aims: The purpose of this study is to find out the survival outcome as well as toxicity profile of Neo-adjuvant chemotherapy with cisplatin and short infusional (3 hours) 5-FU followed by radiotherapy in advanced head and neck malignancies.
Materials and Methods: From June 2002 to December 2003, seventy four patients with advanced head and neck malignancies were planned to be treated with Cisplatin (50 mg / sq. meter) on Days 1 and 2 and 5 - FU (600 mg / sq. meter) on Days 1, 2 and 3 by 3 hour infusion on Day care basis. On completion of four cycles of chemotherapy at 21 days interval, all patients were destined to receive 6000 cGy of radiotherapy to the loco - regional site.
Results: At one year follow up on completion of therapy, 57% patients were alive and 31% patients were disease free. These 31% patients enjoyed a good quality of life in terms of cosmetic and functional deficits. Toxicities were moderate and easily manageable.
Conclusion: The study indicated that neo-adjuvant chemotherapy with Cisplatin and short infusional 5 - FU may be delivered on day care basis and results are comparable with Cisplatin and 96 hours continuous infusional 5 - FU. Thus avoiding the continuous infusional 5 - FU, 7 to 10 days in-patient hospitalization during each cycle may be avoided which is a constrain in developing countries like us.
Keywords
Advanced H and N Mailgnancy, Neo-adjuvant chemotherapy, Cisplatin and short infusional 5-FU
|
|
© Copyright 2005 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|